Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.34 |
| ▸ | ATM | Q13315 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26466448 | 0.82 | ALDH1A1 (0.34) | ALDH1A1MEN1KMT2AATML3MBTL1 | |
| SCHEMBL26100201 | 0.80 | NFKB1 (0.37) | ALDH1A1CTSKMEN1KMT2AATM | |
| SCHEMBL19078479 | 0.79 | ATM (0.41) | ALDH1A1CTSKMEN1KMT2ANR1H2 | |
| SCHEMBL2576337 | 0.74 | MAP4K4 (0.36) | ALDH1A1CTSKMEN1KMT2ANR1H2 | |
| SCHEMBL7714098 | 0.74 | MAP4K4 (0.36) | ALDH1A1CTSKMEN1KMT2ANR1H2 | |
| SCHEMBL21834515 | 0.73 | ATM (0.42) | ALDH1A1CTSKMEN1KMT2AATM | |
| SCHEMBL21818930 | 0.73 | ATM (0.42) | ALDH1A1CTSKMEN1KMT2AATM | |
| SCHEMBL3883677 | 0.73 | NR1H2 (0.43) | ALDH1A1CTSKMEN1KMT2ANR1H2 | |
| SCHEMBL3883681 | 0.73 | NR1H2 (0.43) | ALDH1A1CTSKMEN1KMT2ANR1H2 | |
| SCHEMBL452693 | 0.73 | ADORA1 (0.38) | ALDH1A1NR1H2ATMHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230140132-A1 | ARGINASE INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230140132-A1 | ARGINASE INHIBITORS AND METHODS OF USE | ARG1, ARG2, PRMT1 | ALDH1A1 383/4885CTSK 792/4885MEN1 2856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.